<code id='4CD59161FE'></code><style id='4CD59161FE'></style>
    • <acronym id='4CD59161FE'></acronym>
      <center id='4CD59161FE'><center id='4CD59161FE'><tfoot id='4CD59161FE'></tfoot></center><abbr id='4CD59161FE'><dir id='4CD59161FE'><tfoot id='4CD59161FE'></tfoot><noframes id='4CD59161FE'>

    • <optgroup id='4CD59161FE'><strike id='4CD59161FE'><sup id='4CD59161FE'></sup></strike><code id='4CD59161FE'></code></optgroup>
        1. <b id='4CD59161FE'><label id='4CD59161FE'><select id='4CD59161FE'><dt id='4CD59161FE'><span id='4CD59161FE'></span></dt></select></label></b><u id='4CD59161FE'></u>
          <i id='4CD59161FE'><strike id='4CD59161FE'><tt id='4CD59161FE'><pre id='4CD59161FE'></pre></tt></strike></i>

          Home / comprehensive / explore

          explore


          explore

          author:hotspot    Page View:84968
          Novo Nordisk headquarters -- health coverage from STAT
          LISELOTTE SABROE/Scanpix/AFP via Getty Images

          LEXINGTON, Mass. — New obesity drugs like Wegovy and Zepbound are currently taken once a week, indefinitely. But what if they could be taken once a year instead, like a vaccine?

          That’s a question that Novo Nordisk, the pharma company behind Wegovy, is exploring as it faces increased competition from other drugmakers aiming to develop similar GLP-1-based treatments for obesity.

          advertisement

          “We have a very early think tank on: what would it take us, from a technology point of view and from an ecosystem point of view, to make long-lasting GLP-1 molecules?” Marcus Schindler, Novo’s chief scientific officer, said in an interview with STAT Wednesday. “Could we think about vaccine-like properties, where imagine you had, once a year, an injection with an equivalent of a GLP-1 that really helps you to maintain weight loss and have cardiovascular benefits?”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In